- Home
- PSNL vs BOLD Comparison
PSNL vs BOLD Comparison
Compare PSNL & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PSNL | BOLD |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 746.8M | 26.2M |
| IPO Year | 2019 | 2024 |
Fundamental Metrics
Financial Performance| Metric | PSNL | BOLD |
|---|---|---|
| Price | $8.19 | $1.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $10.71 | $4.00 |
| AVG Volume (30 Days) | ★ 1.5M | 144.6K |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $69,103,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.33 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.83 | $1.00 |
| 52 Week High | $11.40 | $3.12 |
Technical Indicators
Market Signals| Indicator | PSNL | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 43.38 | 51.20 |
| Support Level | $7.68 | $1.17 |
| Resistance Level | $9.10 | $1.37 |
| Average True Range (ATR) | 0.51 | 0.08 |
| MACD | -0.12 | 0.01 |
| Stochastic Oscillator | 22.37 | 34.62 |
Price Performance
Historical ComparisonAbout PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.